New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
07:40 EDTESRX, INSYInsys valuation could be $4 lower on Subsys exclusion, says Wells Fargo
After another research firm stated that Insys' (INSY) Subsys would be placed on Express Scripts' (ESRX) list of excluded drugs, Wells Fargo estimates that such a development could reduce Insys' valuation by about $4. The firm notes that the stock fell $4.16 on July 31 and August 1. It keeps an Outperform rating on the shares.
News For INSY;ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
15:30 EDTESRXExpress Scripts options active after report of possible Humana sale
Express Scripts (ESRX) June 90 weekly and July weekly 83 puts are active on 14K puts (6K calls) after a report of possible Humana (HUM) sale. June and July put option implied volatility is at 23; compared to its 52-week range of 14 to 32. Active put volume suggests traders taking positions for downside price movement.
15:17 EDTESRXExpress Scripts falls in late afternoon
Subscribe for More Information
15:00 EDTESRXExpress Scripts falling, Anthem rising after report of possible Humana sale
Subscribe for More Information
09:16 EDTESRXBofA/Merrill healthcare tech analyst holds analyst/industry conference call
Analyst Willoughby discusses relevant themes across the Healthcare Distribution & Technology subsectors on an Analyst/Industry conference call to be held on June 1 at 11 am.
May 28, 2015
09:24 EDTINSYJefferies sees Pharma M&A continuing, lists 22 possible targets
Jefferies analyst David Steinberg believes the M&A wave in the Pharmaceuticals space that began in 2005 can continue as the key drivers remain largely intact. In a note titled "Who is Next? The Feeding Frenzy in Specialty Pharmaceuticals," Steinberg sees deals continuing amid cheap debt, the push for lower corporate taxes and investors rewarding many acquirers for their transactions. He points out there are now around 100 publicly traded Specialty Pharmaceutical companies following the recent life sciences IPO boom. Potential takeover targets, according to Steinberg, include Valeant (VRX), Shire (SHPG), Perrigo (PRGO), Zoetis (ZTS), Mallinckrodt (MNK), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Pacira (PCRX), Indivior, Insys Therapeutics (INSY), The Medicines Co. (MDCO), Depomed (DEPO), Spectrum (SPPI), KYTHERA (KYTH), Revance (RVNC), XenoPort (XNPT), Mylan (MYL), Akorn (AKRX), Impax (IPXL), Amphastar Pharmaceuticals (AMPH), Anacor (ANAC) and BioDelivery Sciences (BDSI).
May 21, 2015
11:08 EDTESRXExpress Scripts management to meet with Jefferies
Meeting to be held in New York on May 26 hosted by Jefferies.
09:38 EDTESRXExpress Scripts starting to win some business, says Cleveland Research
Cleveland Research is hearing Express Scripts won the state of South Carolina business and renewal rates remain strong and on track to achieve guidance of 94%-97%.
May 20, 2015
13:10 EDTINSYInsys Therapeutics weakness a buying opportunity, says RBC Capital
Subscribe for More Information
12:25 EDTINSYInsys Therapeutics drops following arrest of Alabama doctors
Shares of Insys Therapeutics (INSY) are sharply lower in early afternoon trading after FOX10 News in Alabama reported that Dr. John Patrick Couch and Dr. Xiulu Ruan of Physicians' Pain Specialists of Alabama Pain Center have been arrested on drug and fraud charges. Previously, the Southern Investigative Reporting Foundation stated that Ruan and Couch were the leading prescription writers of Subsys, which is Insys' sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant patients, by an "impressive margin." Shares of Insys are down 8.4% to $54.76 in afternoon trading following the news of the arrests of the doctors. Reference Link
12:18 EDTINSYInsys Therapeutics puts active on sharp pullback
Insys Therapeutics June 50 and 55 puts are active on total put volume of 6,500 contracts (100 calls). June put option implied volatility is at 76, July is at 60 compared to its 90-day average of 62. Active put volume suggests traders taking positions for large upside price movement.
11:51 EDTESRXExpress Scripts' Medco to pay $7.9M to resolve kickback allegations
Medco Health Solutions, a wholly-owned subsidiary of the pharmacy benefit manager Express Scripts Holding Company (ESRX), of Missouri, has agreed to pay the government $7.9M to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act, the Justice Department announced. Medco provides pharmacy benefit management services to clients who receive subsidies under the Medicare Retiree Drug Subsidy program. The settlement resolves allegations that Medco solicited remuneration from AstraZeneca, a pharmaceutical manufacturer, in exchange for identifying Nexium as the “sole and exclusive” proton pump inhibitor on certain of Medco’s prescription drug lists known as formularies. The United States alleged that Medco received some or all of the remuneration from AstraZeneca in the form of reduced prices on the following AstraZeneca drugs: Prilosec, Toprol XL and Plendil. The United States contended that this kickback arrangement between Medco and AstraZeneca (AZN) violated the Federal Anti-Kickback statute, and thereby caused the submission of false or fraudulent claims for Nexium to the Retiree Drug Subsidy Program. In January 2015, the United States and AstraZeneca reached a $7.9M settlement to resolve kickback allegations arising out of the same conduct. This civil settlement resolves a lawsuit filed under the qui tam, or whistleblower, provision of the False Claims Act, which allows private citizens with knowledge of false claims to bring civil actions on behalf of the government and to share in any recovery. The lawsuit was filed by former AstraZeneca employees Paul DiMattia and F. Folger Tuggle, whose share of the settlement has not been determined. The settlement with Medco was the result of a coordinated effort among the Civil Division, the U.S. Attorney’s Office of the District of Delaware and HHS-OIG.
10:00 EDTESRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:05 EDTINSYInsys Therapeutics pipeline growing, underappreciated, says RBC Capital
Subscribe for More Information
May 19, 2015
16:41 EDTESRXExpress Scripts initiated with a Neutral at Baird
Target $94.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use